Page last updated: 2024-08-26

fotemustine and vindesine

fotemustine has been researched along with vindesine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (83.33)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Avril, MF; Bertrand, P; Bizzari, JP; Cour, V; Gerard, B; Khayat, D1
Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M1
Antoine, E; Auclerc, G; Benhammouda, A; Bizzari, JP; Borel, C; Paraiso, D; Petit, T; Rixe, O; Soubrane, C; Weil, M1
Christmann, M; Dietel, M; Kaina, B; Kern, MA; Lage, H; Pick, M; Schadendorf, D1
Kern, MA; Lichter, P; Nessling, M; Schadendorf, D1
Eigentler, TK; Garbe, C1

Reviews

2 review(s) available for fotemustine and vindesine

ArticleYear
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
    Melanoma research, 1992, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine

1992
[Therapy of malignant melanoma at the stage of distant metastasis].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2004, Volume: 55, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Skin Neoplasms; Temozolomide; Time Factors; Tomography, X-Ray Computed; Vindesine

2004

Trials

2 trial(s) available for fotemustine and vindesine

ArticleYear
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
    Melanoma research, 1992, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine

1992
Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
    Melanoma research, 1995, Volume: 5, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Risk; Salvage Therapy; Survival Rate; Treatment Outcome; Vindesine

1995

Other Studies

3 other study(ies) available for fotemustine and vindesine

ArticleYear
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
    Cancer, 1994, Jan-01, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fluorouracil; Forecasting; Humans; In Vitro Techniques; Lymphatic Metastasis; Melanoma; Methotrexate; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Retrospective Studies; Skin Neoplasms; Tumor Cells, Cultured; Vindesine

1994
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance.
    International journal of cancer, 1999, Mar-01, Volume: 80, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carrier Proteins; Cisplatin; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; Drug Resistance, Multiple; Etoposide; Humans; Melanoma; MutL Protein Homolog 1; MutS Homolog 2 Protein; N-Glycosyl Hydrolases; Neoplasm Proteins; Nitrosourea Compounds; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins; RNA, Messenger; Transcription, Genetic; Vindesine

1999
Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines.
    Cytogenetics and cell genetics, 1999, Volume: 87, Issue:3-4

    Topics: Aneuploidy; Antineoplastic Agents; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 9; Cisplatin; DNA Mutational Analysis; DNA Probes; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Etoposide; Genome, Human; Humans; Melanoma; Nitrosourea Compounds; Nucleic Acid Hybridization; Organophosphorus Compounds; Selection, Genetic; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Vindesine

1999